Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results Meeting Abstract
| Authors: | Loriot, Y.; Schuler, M. H.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Palmer, D.; Lugowska, I.; Coward, J.; Corassa, M.; Stuyckens, K.; Liao, H.; Najmi, S.; Hammond, C.; Santiago-Walker, A. E.; Sweiti, H.; Pant, S. |
| Abstract Title: | Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300900 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.3007 |
| Notes: | Meeting Abstract: 3007 -- Meeting also held virtually -- Source: Wos |
